SCHEMBL8293240

SCHEMBL8293240

Cc1ccc2c(c1)C(C)(C)CCN2C(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 4/20 0.54
RARB P10826 4/20 0.54
RARG P13631 2/20 0.54
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 2/20 0.37
HTT P42858 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD11B1 P28845 3/20 0.33
MAPT P10636 3/20 0.33
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
OPRK1 P41145 1/20 0.32
OPRL1 P41146 1/20 0.32
HDAC1 Q13547 2/20 0.31
HDAC6 Q9UBN7 2/20 0.31
POLB P06746 1/20 0.31
CCR2 P41597 1/20 0.31
NOTUM Q6P988 1/20 0.30
HTR1A P08908 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24202326 0.91 RARA (0.46) RARARARBRARGKMT2AKDM4E
SCHEMBL5539777 0.83 RARA (0.39) RARARARBRARGKMT2AKDM4E
SCHEMBL12715253 0.83 RARA (0.53) RARARARBRARGOPRM1OPRD1
SCHEMBL17675521 0.83 RARA (0.53) RARARARBRARGHDAC1HDAC6
SCHEMBL7709957 0.83 RARA (0.53) RARARARBRARGKMT2AKDM4E
SCHEMBL8293242 0.78 RARA (0.48) RARARARBRARGKMT2AKDM4E
SCHEMBL2625755 0.78 RARA (0.48) RARARARBRARGKMT2AKDM4E
SCHEMBL7709737 0.75 RARA (0.43) RARARARBRARGALDH1A1
SCHEMBL7709686 0.75 RARA (0.43) RARARARBRARG
SCHEMBL7706875 0.75 RARA (0.43) RARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11833203-B2 Synthetic retinoids (in cell modulation) UNIVERSITY OF DURHAM 2023-12-05 US disclosed
US-11324825-B2 Synthetic retinoids (in cell modulation) UNIVERSITY OF DURHAM 2022-05-10 US disclosed
US-10759762-B2 Fluorescent synthetic retinoids HIGH FORCE RESEARCH LIMITED (GB) 2020-09-01 US disclosed
US-20190209684-A1 Synthetic Retinoids (in Cell Modulation) UNIVERSITY OF DURHAM (GB) 2019-07-11 US disclosed
US-20190209685-A1 SYNTHETIC RETINOIDS (IN CELL MODULATION) UNIVERSITY OF DURHAM (GB) 2019-07-11 US disclosed
WO-2018029473-A1 SYNTHETIC RETINOIDS (IN CELL MODULATION) UNIVERSITY OF DURHAM (GB) 2018-02-15 WO disclosed
US-20170217893-A1 Fluorescent Synthetic Retinoids HIGH FORCE RESEARCH LIMITED (GB) 2017-08-03 US disclosed
EP-1692097-B1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2009-09-02 EP disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759762-B2 Fluorescent synthetic retinoids RARB, RXRB, RXRA RARA 4/4885RARB 1/4885RARG 5/4885
US-11833203-B2 Synthetic retinoids (in cell modulation) RARA, RARB, RXRA RARA 1/4885RARB 2/4885RARG 4/4885
US-11324825-B2 Synthetic retinoids (in cell modulation) RARA, RARB, RXRA RARA 1/4885RARB 2/4885RARG 4/4885
US-20190209685-A1 SYNTHETIC RETINOIDS (IN CELL MODULATION) RARA, RARB, RXRA RARA 1/4885RARB 2/4885RARG 4/4885
US-20170217893-A1 Fluorescent Synthetic Retinoids RARB, RXRB, RXRA RARA 4/4885RARB 1/4885RARG 5/4885
US-20190209684-A1 Synthetic Retinoids (in Cell Modulation) RARA, RARB, RXRA RARA 1/4885RARB 2/4885RARG 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.